iBu TU is highlighted as a promising oral antiviral candidate for treating SARS-CoV-2 infection and significantly reduced viral loads and improved lung health without adverse effects in a Syrian hamster model infected with SARS-CoV-2.
Abstract
Although the SARS-CoV-2 pandemic is now largely controlled through widespread vaccination and available therapeutics, emerging variants could undermine their overall effectiveness. 4′-Thiouridine (TU) and its 5′-isobutyryl prodrug (iBu TU) were identified as potent inhibitors of SARS-CoV-2 replication across various cell models, including advanced primary human respiratory models. Both compounds exhibited no significant toxicity across a range of cell culture systems, with no signs of mitochondrial damage or elevated lactic acid production. Furthermore, TU and iBu TU tested negative for mutagenicity, aneugenic and clastogenic effects, alleviating concerns about genotoxicity. They also showed no interaction with a broad spectrum of ion channels, GPCRs, and enzymes, further confirming their favorable safety profile. TU is metabolized intracellularly to its active triphosphate form (TU-TP), which effectively disrupts viral RNA replication by acting as a delayed chain terminator. iBu TU is rapidly converted to TU in plasma and displays superior oral bioavailability compared to TU (F = 90% vs 42% in monkeys). In a Syrian hamster model infected with SARS-CoV-2, oral iBu TU significantly reduced viral loads (1.7 to 4.5 log10) and improved lung health without adverse effects. These findings highlight iBu TU as a promising oral antiviral candidate for treating SARS-CoV-2 infection.
The in vitro anti-RdRp, anti-ExoN, and anti-SARS-CoV-2 assays demonstrated the potent inhibitory activities of the CLT molecule and its expected major active metabolite, CLT triphosphate (CLT-TP), on coronaviral replication, with very interesting 50% inhibitory concentration values against the nirmatrelvir-resistant SA...
A. Rabie, Imane G. El Idrissi· RSC Advances· 0 citations
BACKGROUND
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, results in severe acute respiratory illness and has been declared a global public health emergency. Developing effective therapeutic strategies to control the infection remains an urgent priority. The viral spike glycoproteins and proteases play crucial...
Aakrshit Singh, Gaurav Krishna, Shilpi Sonker et al.· Current Organic Synthesis· 0 citations
In vivo mouse studies showed that FMAU treatment provided full protection against lethal VACV and MPXV challenges, while significantly reducing viral loads in lung tissues, and oral FMAU administration retained potent therapeutic efficacy against MPXV in a mouse model of MPXV infection.
Ting-Ting Zheng, Yong Feng, Chang Xu et al.· Emerging Microbes and Infect...· 0 citations
The ongoing emergence and reemergence of RNA viruses from multiple viral families highlights the urgent need for broad‐spectrum antiviral therapeutics. To address this issue, a series of 4′‐azido fleximer nucleoside analogs were synthesized and evaluated for broad‐spectrum antiviral activity against pathogens of epidem...
Kyle A. Davis, Ryan L. Slack, Thomas R. Foulkes et al.· ChemMedChem· 0 citations
The persistent global threat posed by emerging and re-emerging RNA viruses, including SARS-CoV-2, influenza A(H1N1)pdm09, DENV-2, and CHIKV, highlights the critical need for novel and broad-spectrum antiviral agents. Building upon the established antiviral activity of the quinoline scaffold, this study employed a molec...
A. D. de Carvalho, N. Fintelman-Rodrigues, Victória Toledo Diniz de Camargo et al.· Viruses· 0 citations
The ongoing emergence of SARS-CoV-2 mutations underscores the urgent need for new antivirals that target key viral proteins. This study describes the design, synthesis, and evaluation of two series of 1,3,4-oxadiazole-tethered N-substituted isatin hybrids as inhibitors of the SARS-CoV-2 main protease (Mpro): 1,2,3-tria...
T. Al-Warhi, Md Sofequl Islam Mukim, Zainab M. Elsayed et al.· RSC Advances· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.